Amatuximab (MORAb-009) is an investigational monoclonal antibody that has been studied for its potential use in the treatment of mesothelioma.
MORAb-009-201 Phase 2 First-line Mesothelioma (Active; not recruiting)
A Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM) (ARTEMIS).
For more information visit ClinicalTrials.gov. (Identifier: NCT02357147)
For more information about Amatuximab, please click here.
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.